Compare MMM & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MMM | SNY |
|---|---|---|
| Founded | 1902 | 1994 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.8B | 119.4B |
| IPO Year | N/A | N/A |
| Metric | MMM | SNY |
|---|---|---|
| Price | $158.10 | $46.74 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 6 |
| Target Price | ★ $174.78 | $61.50 |
| AVG Volume (30 Days) | ★ 3.2M | 2.8M |
| Earning Date | 01-20-2026 | 01-29-2026 |
| Dividend Yield | 1.87% | ★ 3.46% |
| EPS Growth | N/A | ★ 105.93 |
| EPS | 6.00 | ★ 8.67 |
| Revenue | $24,948,000,000.00 | ★ $53,890,648,839.00 |
| Revenue This Year | $1.42 | $1.73 |
| Revenue Next Year | $3.01 | $6.49 |
| P/E Ratio | $25.98 | ★ $5.33 |
| Revenue Growth | ★ 1.52 | N/A |
| 52 Week Low | $121.98 | $44.62 |
| 52 Week High | $174.69 | $60.12 |
| Indicator | MMM | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 40.08 | 41.54 |
| Support Level | $153.07 | $45.25 |
| Resistance Level | $173.06 | $48.17 |
| Average True Range (ATR) | 4.11 | 0.73 |
| MACD | -0.84 | -0.15 |
| Stochastic Oscillator | 25.21 | 34.35 |
3M, a multinational conglomerate founded in 1902, sells tens of thousands of products ranging from sponges to respirators. The firm is well known for its extensive research and development capabilities, and it is a pioneer in inventing new use cases for its proprietary technologies. 3M is organized across three business segments: safety and industrial (representing around 44% of revenue), transportation and electronics (36%), and consumer (20%). The firm recently spun off its healthcare business, now known as Solventum. Nearly half of 3M's revenue comes from outside the Americas.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.